{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:41:01Z","timestamp":1761198061564},"reference-count":0,"publisher":"Ecancer Global Foundation","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ecancer"],"DOI":"10.3332\/ecancer.2022.1404","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T13:19:37Z","timestamp":1653916777000},"source":"Crossref","is-referenced-by-count":4,"title":["Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib"],"prefix":"10.3332","volume":"16","author":[{"given":"Shubham","family":"Tomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakhan","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1871","published-online":{"date-parts":[[2022,5,30]]},"container-title":["ecancermedicalscience"],"original-title":[],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T13:19:37Z","timestamp":1653916777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ecancer.org\/en\/journal\/article\/1404-fumarate-hydratase-deficient-renal-cell-carcinoma-in-extended-remission-with-bevacizumab-and-erlotinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3332\/ecancer.2022.1404","relation":{},"ISSN":["1754-6605"],"issn-type":[{"value":"1754-6605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}